Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Cullinan Therapeutics, Inc.

CGEM · Nasdaq · CIK 0001789972 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

11 Form 4 transaction lines observed in the same window
5 sales · 6 option, withholding, award, gift or other lines

Last qualifying purchase2025-10-28 · Lynx1 Capital Management LP; Nichols Weston · $1.4M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Michaelson JenniferChief Scientific Officer
○▼○▼○▼○▼
SUMER JACQUELYN LChief Legal Officer
○
Fenton Mary KayChief Financial Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-10-28 · Lynx1 Capital Management LP; Nichols Weston.

Recent Form 4 activity

1Purchases
28Sales
11Other Form 4 lines
30SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING5 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
7,634,127
Previous report
9,629,017
Avg daily volume
1,505,393
Days to cover
5.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-10-28Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share165,667USD 8.40USD 1,391,603SEC filing ↗
2025-10-17Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock32,217USD 7.84USD 252,581SEC filing ↗
2025-10-16Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock150,000USD 8.86USD 1,329,000SEC filing ↗
2025-10-15Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock51,500USD 7.94USD 408,910SEC filing ↗
2025-10-14Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")15,032USD 7.59USD 114,093SEC filing ↗
2025-10-10Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock277,298USD 7.36USD 2,040,913SEC filing ↗
2025-10-09Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock626,043USD 6.70USD 4,194,488SEC filing ↗
2025-10-08Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")556,300USD 6.46USD 3,593,698SEC filing ↗
2022-06-06AHMED NADIMPurchase (P)Common Stock8,090USD 12.40USD 100,316SEC filing ↗
2022-06-01BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common Stock751,396USD 11.00USD 8,265,356SEC filing ↗
2022-05-13BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common Stock109,900USD 9.14USD 1,004,486SEC filing ↗
2022-05-12BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common Stock1,000,000USD 9.06USD 9,060,000SEC filing ↗
2022-04-01BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common Stock276,000USD 10.75USD 2,967,000SEC filing ↗
2021-01-12Trigilio JeffreyPurchase (P)Common Stock2,250USD 21.00USD 47,250SEC filing ↗
2021-01-12MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.Purchase (P)Common Stock300,000USD 21.00USD 6,300,000SEC filing ↗

Form 4 evidence

40 transaction lines in the latest 365-day window; 308 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08Michaelson JenniferSale (S)Common Stock8,000USD 21.57USD 172,560SEC filing ↗
2026-09-08Michaelson JenniferOption exercise / conversion (M)Common Stock4,000USD 4.30USD 17,200SEC filing ↗
2026-08-13Michaelson JenniferSale (S)Common Stock30,000USD 20.26USD 607,800SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08Michaelson JenniferSale (S)Common Stock8,000USD 21.57USD 172,560SEC filing ↗
2026-09-08Michaelson JenniferOption exercise / conversion (M)Common Stock4,000USD 4.30USD 17,200SEC filing ↗
2026-08-13Michaelson JenniferSale (S)Common Stock30,000USD 20.26USD 607,800SEC filing ↗
2026-08-13Michaelson JenniferOption exercise / conversion (M)Common Stock30,000USD 4.30USD 129,000SEC filing ↗
2026-07-06Michaelson JenniferSale (S)Common Stock8,000USD 17.82USD 142,560SEC filing ↗
2026-07-06Michaelson JenniferOption exercise / conversion (M)Common Stock4,000USD 4.30USD 17,200SEC filing ↗
2026-06-30SUMER JACQUELYN LAward / grant (A)Common Stock2,470USD 8.60USD 21,242SEC filing ↗
2026-06-30Fenton Mary KayAward / grant (A)Common Stock1,541USD 8.60USD 13,253SEC filing ↗
2026-05-05Michaelson JenniferSale (S)Common Stock8,000USD 14.62USD 116,996SEC filing ↗
2026-05-05Michaelson JenniferOption exercise / conversion (M)Common Stock4,000USD 4.30USD 17,200SEC filing ↗
2026-03-05Michaelson JenniferSale (S)Common Stock8,000USD 15.68USD 125,440SEC filing ↗
2026-03-05Michaelson JenniferOption exercise / conversion (M)Common Stock4,000USD 4.30USD 17,200SEC filing ↗
2026-02-25Michaelson JenniferSale (S)Common Stock1,780USD 14.14USD 25,169SEC filing ↗
2026-02-24SUMER JACQUELYN LSale (S)Common Stock3,601USD 14.47USD 52,106SEC filing ↗
2026-02-24Michaelson JenniferSale (S)Common Stock3,601USD 14.47USD 52,106SEC filing ↗
2026-02-24Jones Jeffrey AlanSale (S)Common Stock4,582USD 14.47USD 66,302SEC filing ↗
2026-02-24AHMED NADIMSale (S)Common Stock13,515USD 14.47USD 195,562SEC filing ↗
2026-02-23Michaelson JenniferSale (S)Common Stock1,752USD 13.99USD 24,510SEC filing ↗
2026-02-20SUMER JACQUELYN LSale (S)Common Stock3,742USD 13.62USD 50,966SEC filing ↗
2026-02-20Michaelson JenniferSale (S)Common Stock11,742USD 14.08USD 165,366SEC filing ↗
2026-02-20Michaelson JenniferOption exercise / conversion (M)Common Stock8,000USD 4.30USD 34,400SEC filing ↗
2026-02-20Jones Jeffrey AlanSale (S)Common Stock4,982USD 13.62USD 67,855SEC filing ↗
2026-02-20Fenton Mary KaySale (S)Common Stock4,398USD 13.62USD 59,901SEC filing ↗
2026-02-20AHMED NADIMSale (S)Common Stock16,381USD 13.62USD 223,109SEC filing ↗
2026-02-18Michaelson JenniferAward / grant (A)Common Stock57,500USD 0.00USD 0SEC filing ↗
2026-02-18Fenton Mary KayAward / grant (A)Common Stock68,750USD 0.00USD 0SEC filing ↗
2026-02-12Michaelson JenniferSale (S)Common Stock416USD 12.03USD 5,004SEC filing ↗
2026-01-22Michaelson JenniferSale (S)Common Stock4,000USD 12.30USD 49,200SEC filing ↗
2025-12-31Fenton Mary KayAward / grant (A)Common Stock27USD 6.49USD 175SEC filing ↗
2025-12-23AHMED NADIMSale (S)Common Stock9,922USD 10.01USD 99,319SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCGEM
CIK0001789972
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history308 transaction lines from 2021-01-07 to 2026-09-08
25 P purchase lines · 193 S sale lines · 90 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.